Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee Holger Weis BOSTON , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology ,
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings R aise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON , Nov.
Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook Outlines Additions of Five Highly Qualified Industry Veteran s to Board Over the Last 18 Months BOSTON , Nov. 20, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced
– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM, and a Confirmed Partial Response – – Updated Interim Data from Ongoing Phase 1 Study of Controlled IL-12 in Combination with Nivolumab Show a mOS of 16.9 Months
– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings – – Former Chief Medical Officer for Servier Pharmaceuticals ; Oncology R &D Leadership R oles at Shire, Pfizer and Sanofi –
– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director – – Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercial and Financial Leadership – – Scott
BOSTON , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at
– Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library “hotspot” trial – – Eden BioCell on track for IND filing i n Taiwan for autologus CAR-T clinical trial this year based on rapid personalized manufacturing ; several patients dosed under compassionate
Urges Shareholders to Sign and Return Ziopharm’s GREEN Consent Revocation Card Emphasizes that Substantial Board Refr eshment is Already in Process Reiterates Commitment to Implementing Strategy and Delivering Significant Value to S hareholders Questions WaterMill’s Attempt to Seize Outsize d
BOSTON , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended September 30, 2020